智通财经APP获悉，腾盛博药-B(02137)午后重挫14%，截至发稿，跌11.89%，报2.52港元，成交额1683.76万港元。
消息面上，腾盛博药近日公布的2024年业绩报告显示，公司全年实现其他收入1.41亿元，同比减少13.6%，去年亏损额为5.12亿元，同比扩大177.9%。据悉，公司目前暂无产品商业化，收入主要来自银行利息和政府补助。
公开资料显示，2021年腾盛博药研发的单克隆中和抗体安巴韦单抗/罗米司韦单抗的联合疗法上市申请获国家药监局批准，成为国内首家自主知识产权新冠病毒中和抗体联合治疗药物。但这款药物实现商业化后仅8个月便被宣布停产，据2022年年报披露的财务数据，该药物仅为腾盛博药带来收入5160万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.